

Curriculum Vitae
ANNE SMITH, RN, CCRC

Anne B. Smith
5/14/07

Business Address:
National Clinical Research, Inc.
2809 Emerywood Parkway
Suite 140
Richmond, VA 23294
804-672-2133 ext. 28

EDUCATION

1975 State Registered Nurse
 Charing Cross School of Nursing
 London, England

1972 Ophthalmic Nursing Diploma
 Bristol Eye Hospital
 Bristol, England

PROFESSIONAL EXPERIENCE

Nov 2003 – present Certified Clinical Research Coordinator
 National Clinical Research
 Richmond, VA

May 2001 – Nov 2003 Clinical Research Coordinator
 National Clinical Research
 Richmond, VA

Jul 2000 – Jul 2001 Staff Nurse
 Cardiopulmonary Rehab
 Henrico Doctors Hospital
 Richmond, VA

1999 – Jun 2000 Nurse Consultant
 Children's Medical Call Line
 Henrico Doctors Hospital
 Richmond, VA

1989 – 1999 Staff Nurse
 PICU/ICU
 St. Mary's Hospital
 Richmond, VA

1984 – 1988 Staff Nurse
 PICU
 Fort Worth Children's Medical Center
 Fort Worth, TX

1981 – 1984 Assistant Head Nurse
 PICU
 Fort Worth Children's Medical Center
 Fort Worth, TX

1979 – 1981 Assistant Head Nurse

ICU
Harris Hospital Methodist
Fort Worth, TX

1976 – 1979
General Staff Nurse
ICU
Harris Hospital Methodist
Fort Worth, TX

LICENSES & CERTIFICATONS

Current	ACLS Certification
11/2003 – present	Certified Clinical Research Coordinator
1988 – present	Registered Nurse, Commonwealth of Virginia
1977 –1988	Registered Nurse, Texas

CLINICAL RESEARCH EXPERIENCE

Study Coordinator

A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneously administered a-200 in obese subjects, Coordinator, Amgen (Protocol (A-200) 990768), Dec99 – Oct01.

A phase III, multi-center, two arm study to assess the efficacy and safety of SCH39166 of obesity, Coordinator, Schering Plough (Protocol P00396), Nov99 – Oct01.

A phase III, multicenter, two-arm study to assess the efficacy and safety of SCH 39166 in the treatment of obesity in subjects with hypertension and/or dyslipidemia, Schering Plough (Protocol P01551), May01 – Jul01.

A multicenter, double-blind, randomized, parallel-group study investigating the clinical effects of Montelukast in patients with seasonal allergic rhinitis over a 4-week treatment period – Fall 2001 (Protocol 240-00), Merck, Jul01 – Mar02.

A phase III, 12- month, double blind, randomized, placebo group, placebo controlled, efficacy and safety study of AXOKINE® in overweight and obese subjects with a 12-month open-label extension phase (Protocol AX15-OB-0008), Celeris/Regeneron, Jul01 – Dec03.

A randomized, double-blind, placebo-controlled, parallel-group, fixed dose, multicenter study of weight-reducing and prevention of weight regain effects and safety of SR141716 in obese patients with or without comobidities (Protocol EFC4743), ICON/Sanofi~Synthelabo, Sep01 –Jun04.

An Open-label, Randomized, Multi-center, Phase IIIb, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with Rosuvastatin in High Risk Subjects with Type IIa and IIb Hypercholesterolemia (Protocol 4522IL/0068), ICON/Asta Zeneca, Sep01 – Oct04.

A randomized, double-blind, dose ranging, dose comparison-controlled trial to determine the safety and efficacy of BMS-298585 in patients with Type 2 Diabetes (Protocol CV168-006), BMS, Oct01 – Aug06.

A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study of weight-reducing effect and safety of SR141716 in obese patients with type 2 diabetes (Protocol EFC4736), Sanofi~Synthelabo, Oct01 – Jul04.

